Is HAVN Life Sciences Inc. (HAVLF) a Buy, Sell, or Hold?
HAVN Life Sciences Inc.
PNK:HAVLF
$0.0052 USD
$0.0 (-48.0%)
- Volume
- 22.1K
- Average Volume
- 230
- Market Capitalization
- $2.82B
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $0.10
- Year Low
- $0.00
- Payout Ratio
- $0.00
- Current Ratio
- $0.00
Industry, Sector & symbol
| Stock Exchange | Other OTC |
| CEO | Mr. Tim Moore |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | HAVLF |
| CUSIP | None |
| CIK | None |
| Web | https://www.havnlife.com |
| Phone | 604-687-7130 |
| Currency | USD |
| Employees | 6 |
| Country | CA |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Cash Ratio | 0.00 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | 0.00 |
| Price / Cash Flow | 0.00 |
| Price / Book | 0.00 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0 |
| Trailing P/E Ratio | 0.00 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $- |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
Financials Score
| AltmanZ Score | |
| Piotroski Score | 4.00 |
| Working Capital | - |
| Total Assets | - |
| Ebit | -778.62K |
| Market Cap | 2.82B |
| Total Liabilities | - |
Poll Results
About HAVN Life Sciences Inc. (PNK:HAVLF) Stock
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada. ...
HAVN Life to Present at Upcoming LD Micro Invitational XII
2022-06-06 11:38:00
CEO, Tim Moore will share recent partnership and distribution news and a roadmap for the Company's plans for the next quarterVancouver, British Columbia--(Newsfile Corp. - June 6, 2022) - Havn Life Sciences Inc. (CSE: HAVN) (OTC Pink: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life"), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and cognitive function, is announcing that CEO, Tim Moore will be presenting at the LD Micro Invitational XII, taking place June 7-9, 2022 at the Four Seasons Westlake Village in...
2022-04-30 08:00:00
VANCOUVER, BC / ACCESSWIRE / April 30, 2022 / HAVN Life Sciences Inc. (CSE:HAVN) (OTC:HAVLF) (FSE:5NP) , a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, today announced that it will be presenting at the Planet MicroCap Showcase 2022 at the Bally's Hotel & Casino in Las Vegas, NV on Wednesday, May 4, 2022 at 9:00 a.m. PST. Tim Moore, CEO of HAVN Life Sciences Inc.,will be hosting the presentation and answering questions from investors.
HAVN Life Announces Supply and Distribution MOU with Mycrodose Therapeutics
2021-09-23 09:30:00
The partnership is a integral step in the The Company's path to market in the U.S., achieving one of its most important milestones to-date VANCOUVER, BC / ACCESSWIRE / September 23, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, is thrilled to announce a partnership with California-based Mycrodose Therapeutics, one of only a few private companies that has been granted a Schedule I License to research four (4) psychedelic compounds including psilocybin, MDMA, DMT, & LSD by the United States Drug Enforcement Agency (DEA). HAVN Life will work with its partners to export their naturally derived psilocybin to Mycrodose Therapeutics, where it will be used in the development of advanced drug delivery (ADD) systems to treat mental health and cognitive degenerative diseases, as well as be distributed to appropriately licenced customers in the U.S. "We are excited to have forged this partnership with Mycrodose Therapeutics, building an important link in our supply chain to service our Supply Agreement partners in the US," says HAVN Life CEO Tim Moore.
HAVN Life Announces Distribution Deal with Horizon Grocery + Wellness
2021-09-21 08:00:00
VANCOUVER, BC / ACCESSWIRE / September 21, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of active pharmaceutical ingredients that support brain health and enhance the capabilities of the mind, is pleased to announce their partnership with Horizon Grocery + Wellness, Western Canada's leading distributor of organic and natural foods, natural personal care items, and nutritional health supplements (the "Distribution Deal"). Horizon will distribute the full portfolio of HAVN Life's line natural health products, which launched this June.
HAVN Life Signs Agreement to Supply Psilocybin for Mycotopia Therapies
2021-08-25 08:00:00
The partnership will further industry growth for naturally derived psilocybin VANCOUVER, BC / ACCESSWIRE / August 25, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of the mind, recently signed an agreement to supply naturally-derived psilocybin to Mycotopia Therapies (OTC: TPIA) for their psychedelic therapies. Headquartered in Florida, Mycotopia Therapies uses psilocybin to treat people dealing with anxiety, depression, bipolar disorders, PTSD, ADHD, autism, and addictions.
Frequently Asked Questions
-
What is the current HAVN Life Sciences Inc. (HAVLF) stock price?
-
HAVN Life Sciences Inc.(PNK:HAVLF) stock price is $0.0052 in the last trading session. During the trading session, HAVLF stock reached the peak price of $4 while $1.0E was the lowest point it dropped to. The percentage change in HAVLF stock occurred in the recent session was --48.0% while the dollar amount for the price change in HAVLF stock was -$-0.0.
-
HAVLF's industry and sector of operation?
-
The PNK listed HAVLF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of HAVLF?
-
Ms. Jenna Pozar | Chief Operations Officer
Mr. Tim Moore | Interim Chief Financial Officer, Chief Executive Officer & Chairman
Mr. Paul More | Controller
|
| -
How many employees does HAVLF have?
-
Number of HAVLF employees currently stands at 6. HAVLF operates from 22071 Fraserwood Way, Richmond, BC V6W 1J5, CA.
-
Link for HAVLF official website?
-
Official Website of HAVLF is: https://www.havnlife.com
-
How do I contact HAVLF?
-
HAVLF could be contacted at phone #604-687-7130 and can also be accessed through its website. HAVLF operates from 22071 Fraserwood Way, Richmond, BC V6W 1J5, CA.
-
How many shares of HAVLF are traded daily?
-
The average number of HAVLF shares traded daily for last 3 months was 230.
-
What is the market cap of HAVLF currently?
-
The market value of HAVLF currently stands at $2.82B with its latest stock price at $0.0052